Analytical Data
-
Gene name
PTPRD
- Application
-
Alternative Names
PTPR-D; HPTP; HPTP-DELTA; HPTPD; PTPD; R-PTP-DELTA; Receptor-type tyrosine-protein phosphatase delta
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P23468
-
Expression Region
Glu21~Ala219
-
Molecular Weight
33kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
PTPRD (Protein Tyrosine Phosphatase Receptor Type D) is a member of the receptor type protein tyrosine phosphatase family, which plays a crucial role in cellular signaling processes by regulating tyrosine phosphorylation states of proteins. Abnormalities in PTPRD expression and function have been implicated in several diseases, including cancer, neurodegenerative disorders, and cardiovascular diseases. Recent studies have highlighted the significance of PTPRD as a tumor suppressor, as its loss or mutation is often associated with various malignancies, particularly in gliomas and other brain tumors. The reconstitution of PTPRD in cell models has provided insights into its biological functions, and its role in modulating key signaling pathways such as the MAPK and PI3K-AKT pathways is under investigation. Furthermore, given the phosphatase's unique structural features and the potential for targeted therapeutics, researchers are increasingly focused on developing recombinant forms of PTPRD to explore its biochemical properties and therapeutic applications. Understanding the mechanisms by which PTPRD exerts its effects may lead to novel strategies for treating diseases linked to its dysfunction, emphasizing the importance of ongoing research in this area.
